Un article du Wall Street Journal présente des explications concernant le retard pris par la Chine pour valider le vaccin BioNtech.
China’s government is slow-rolling approval of its first foreign Covid-19 vaccine out of concern it could undermine confidence in Chinese vaccines, delivering further evidence of the tenacity of vaccine nationalism in the face of a resurgent pandemic.
Chinese health authorities worry that public doubts about Chinese vaccines stemming from approval of Germany’s BioNTech SE’s vaccine could disrupt the country’s plans to use the homegrown shots to reach an ambitious vaccination goal before the end of the year, according to people familiar with the deliberations.
(...)
In addition, the delay buys more time for Chinese drugmakers to introduce their own mRNA vaccines, according to the people and drug industry executives in China.
China’s government is slow-rolling approval of its first foreign Covid-19 vaccine out of concern it could undermine confidence in Chinese vaccines, delivering further evidence of the tenacity of vaccine nationalism in the face of a resurgent pandemic.
Chinese health authorities worry that public doubts about Chinese vaccines stemming from approval of Germany’s BioNTech SE’s vaccine could disrupt the country’s plans to use the homegrown shots to reach an ambitious vaccination goal before the end of the year, according to people familiar with the deliberations.
(...)
In addition, the delay buys more time for Chinese drugmakers to introduce their own mRNA vaccines, according to the people and drug industry executives in China.